HTS of Rab9 promoter activators

描述（由申请人提供）：由于与蛋白质或基因接触中枢神经系统相关的严重障碍，溶酶体期疾病（lsd）如尼曼-皮克C型病（NPC）的治疗模式目前不存在，而且这些罕见的孤儿疾病没有吸引制药公司的兴趣，进一步导致缺乏任何形式的治疗前景。我们已经开发了一种新的范例，称为“孤儿受体旁路治疗”（ORByT），以解决这些疾病。这种模式假定存在内源性“抑制”蛋白，其表达可以显著改善LSD的发病机制。目标是鉴定/发现可以调节这些蛋白质表达的小化合物，并为这些破坏性疾病提供一种新的治疗方式。我们之前已经证明小的GTPase蛋白Rab9满足这一要求，并且可以作为NPC表型的抑制因子。因此，我们建议首先开展：

DESCRIPTION (provided by applicant): Treatment modalities for lysosomal stage diseases (LSDs) with neuropathology such as Niemann-Pick Type C Disease (NPC) are currently non-existent due to the severe obstacles associated with accessing the central nervous system with proteins or genes, Also, these rare orphan disorders do not attract the interest of pharmaceutical companies, further contributing to the lack of prospects for any form of treatment of therpy. We have developed a new paradigm, termed "Orphan Receptor Bypass Therapy" (ORByT), to address these disorders. This paradigm posits the existence of endogenous "suppressor" proteins whose expression can dramatically improve LSD pathogenesis. The goal is the identification/discovery of small chemical compounds that can modulate the expression of these proteins and provide a new treatment modality for these devastating disorders. We have previously shown that the small GTPase protein Rab9 meets this requirement and can act as suppressor of the NPC phenotype. Thus, we propose to first carry out: * High throughput screening for identification of small molecules that upregulate Rab9 expression, utilizing the MLSCN (Molecular Libraries Screening Center Network) compound collection for drug-like small chemical molecules, and * Characterize and confirm positive hits, using in vitro assay, for their therapeutic potential in the treatment of NPC1 disease, * These studies will result in the identification of candidate compounds that will ultimately be evaluated in vivo in an NPC mouse model to determine their therapeutic potential and future drug development.